Literature DB >> 2194130

Designer and catalytic antibodies.

R D Mayforth1, J Quintáns.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2194130     DOI： 10.1056/NEJM199007193230306

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.

Authors:  Katrin F Nickel; Göran Ronquist; Florian Langer; Linda Labberton; Tobias A Fuchs; Carsten Bokemeyer; Guido Sauter; Markus Graefen; Nigel Mackman; Evi X Stavrou; Gunnar Ronquist; Thomas Renné
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

Review 2.  The biotechnology and applications of antibody engineering.

Authors:  R Rapley
Journal:  Mol Biotechnol       Date:  1995-04       Impact factor: 2.695

3.  Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III.

Authors:  Jenny Björkqvist; Steven de Maat; Urs Lewandrowski; Antonio Di Gennaro; Chris Oschatz; Kai Schönig; Markus M Nöthen; Christian Drouet; Hal Braley; Marc W Nolte; Albert Sickmann; Con Panousis; Coen Maas; Thomas Renné
Journal:  J Clin Invest       Date:  2015-07-20       Impact factor: 14.808

4.  Aspects of antibody-catalyzed primary amide hydrolysis.

Authors:  R C Titmas; T S Angeles; R Sugasawara; N Aman; M J Darsley; G Blackburn; M T Martin
Journal:  Appl Biochem Biotechnol       Date:  1994 May-Jun       Impact factor: 2.926

Review 5.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.